Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Clayton

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
Alzheimer'S Research & Therapy|September 21, 2018
Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE)Stephen Salloway, Lee A Honigberg, William Cho, et al.
Lancet (London, England)|June 27, 2003
Genome-wide mapping of human loci for essential hypertensionMark Caulfield, Patricia Munroe, Janine Pembroke, et al.
The Lancet. Neurology|July 19, 2025
Safety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension studyAmit Bar-Or, Michal Dufek, Hrvoje Budincevic, et al.
Science Translational Medicine|June 17, 2021
A randomized controlled trial to isolate the effects of fasting and energy restriction on weight loss and metabolic health in lean adultsIain Templeman, Harry Alex Smith, Enhad Chowdhury, et al.
Hypertension (Dallas, Tex. : 1979)|November 1, 2006
Polymorphic variation in the 11beta-hydroxylase gene associates with reduced 11-hydroxylase efficiencyMarianne Barr, Scott M MacKenzie, Elaine C Friel, et al.
Hypertension (Dallas, Tex. : 1979)|June 7, 2006
Increased support for linkage of a novel locus on chromosome 5q13 for essential hypertension in the British Genetics of Hypertension StudyPatricia B Munroe, Chris Wallace, Ming-Zhan Xue, et al.
Alzheimer'S & Dementia (New York, N. Y.)|June 30, 2018
The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical <i>PSEN1</i> E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohortPierre N Tariot, Francisco Lopera, Jessica B Langbaum, et al.
Genome Research|May 3, 2003
Haplotype structure, LD blocks, and uneven recombination within the LRP5 geneRebecca C J Twells, Charles A Mein, Michael S Phillips, et al.
JAMA Neurology|September 19, 2022
Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled TrialsSusanne Ostrowitzki, Tobias Bittner, Kaycee M Sink, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 1, 2022
Sex differences in cognitive resilience in preclinical autosomal-dominant Alzheimer's disease carriers and non-carriers: Baseline findings from the API ADAD Colombia TrialClara Vila-Castelar, Pierre N Tariot, Kaycee M Sink, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Alzheimer'S Research & Therapy|September 21, 2018
Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE)Stephen Salloway, Lee A Honigberg, William Cho, et al.
Lancet (London, England)|June 27, 2003
Genome-wide mapping of human loci for essential hypertensionMark Caulfield, Patricia Munroe, Janine Pembroke, et al.
The Lancet. Neurology|July 19, 2025
Safety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension studyAmit Bar-Or, Michal Dufek, Hrvoje Budincevic, et al.
Science Translational Medicine|June 17, 2021
A randomized controlled trial to isolate the effects of fasting and energy restriction on weight loss and metabolic health in lean adultsIain Templeman, Harry Alex Smith, Enhad Chowdhury, et al.
Hypertension (Dallas, Tex. : 1979)|November 1, 2006
Polymorphic variation in the 11beta-hydroxylase gene associates with reduced 11-hydroxylase efficiencyMarianne Barr, Scott M MacKenzie, Elaine C Friel, et al.
Hypertension (Dallas, Tex. : 1979)|June 7, 2006
Increased support for linkage of a novel locus on chromosome 5q13 for essential hypertension in the British Genetics of Hypertension StudyPatricia B Munroe, Chris Wallace, Ming-Zhan Xue, et al.
Alzheimer'S & Dementia (New York, N. Y.)|June 30, 2018
The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical <i>PSEN1</i> E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohortPierre N Tariot, Francisco Lopera, Jessica B Langbaum, et al.
Genome Research|May 3, 2003
Haplotype structure, LD blocks, and uneven recombination within the LRP5 geneRebecca C J Twells, Charles A Mein, Michael S Phillips, et al.
JAMA Neurology|September 19, 2022
Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled TrialsSusanne Ostrowitzki, Tobias Bittner, Kaycee M Sink, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 1, 2022
Sex differences in cognitive resilience in preclinical autosomal-dominant Alzheimer's disease carriers and non-carriers: Baseline findings from the API ADAD Colombia TrialClara Vila-Castelar, Pierre N Tariot, Kaycee M Sink, et al.
Pageof 7